Caspofungin for Pneumocystis Pneumonia in PLWHIV.

Launched by INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS · Nov 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called caspofungin to treat Pneumocystis pneumonia (PCP) in people living with HIV/AIDS. PCP is a serious lung infection that can be life-threatening, especially for those with weakened immune systems. The current standard treatment is another medication, but some people have safety concerns about it. This trial aims to find out if caspofungin, which has shown promise in other studies, could be a safer and effective alternative for treating this infection.

To join the trial, participants need to have a diagnosis of probable or proven PCP and must undergo certain lab tests when they are admitted to the hospital. The trial is open to individuals aged 6 months to 90 years and does not limit participation to any specific gender. If eligible, participants will receive caspofungin and will be monitored closely throughout the study. This research is important because it could lead to better treatment options for those facing this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section).
• • Have clinical laboratory and virological diagnostic laboratory studies at the time of admission.
• * Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.:
• • Proven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism.
• Exclusion Criteria:
• • With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B).
• • Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.